ISRCTN37367725 https://doi.org/10.1186/ISRCTN37367725

Trial of chemotherapy utilising carboplatin, vincristine, cyclophosphamide and etoposide for the treatment of central nervous system primitive neurectodermal tumours of childhood

Submission date 01/07/2001	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 01/07/2001	**Overall study status** Completed	
Last Edited 23/01/2019	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

ClinicalTrials.gov (NCT)
NCT00003859

Protocol serial number
CNS9102

Study information

Scientific Title
Trial of chemotherapy utilising carboplatin, vincristine, cyclophosphamide and etoposide for the treatment of central nervous system primitive neurectodermal tumours of childhood

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Brain and nervous system cancer

Interventions
All patients receive surgery followed by either:
1. Schedule A: Radiotherapy alone
2. Schedule B: Initial chemotherapy (carboplatin, vincristine, cyclophosphamide and etoposide) followed by radiotherapy

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
Carboplatin, vincristine, cyclophosphamide, etoposide

Primary outcome(s)
Not provided at time of registration

Key secondary outcome(s))
Not provided at time of registration

Completion date
28/01/2000

Eligibility

Key inclusion criteria
1. Aged 3 to 16 years
2. Survival period of at least 1 week following surgery
3. Post-operative Computed Tomography (CT) scan and myelogram
4. No concomitant haematological disorder
5. No previous history of malignant disease

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Child

Lower age limit
3 years

Upper age limit
16 years

Sex
All

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/01/1998

Date of final enrolment
28/01/2000

Locations

Countries of recruitment
United Kingdom

England

Study participating centre

MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Cancer Research UK (CRUK) (UK)

ROR
https://ror.org/054225q67

Funder(s)

Funder type
Charity

Funder Name
Cancer Research UK

Alternative Name(s)
CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type
Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output	Date	Date	Peer	Patient-

type	Details	created	added	reviewed?	facing?
Results article	patient stratification results	15/08/2004		Yes	No
Results article	follow-up results	20/09/2007		Yes	No
Results article	results for supratentorial primitive neuro-ectodermal tumours (SPNET) subset	01/07/2009		Yes	No
Results article	radiotherapy duration results	15/03/2004	23/01/2019	Yes	No
Results article	results	15/04/2003	23/01/2019	Yes	No